Latest Oncology News

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021

Gina Mauro

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Conor Killmurray

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

September 19th 2021

Matthew Fowler

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

September 19th 2021

Jamie Cesanek

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021

Colleen Moretti

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Latest Oncology Videos

All Oncology News

Dr. Osarogiagbon on Geographic Disparities in Lung Cancer Mortality Rates in the United States

September 11th 2021

Raymond U. Osarogiagbon, MD, FACP

Raymond U. Osarogiagbon, MD, discusses geographic disparities in lung cancer mortality rates across the United States.

MSI-H/dMMR Prostate Cancer Linked With Response to Checkpoint Blockade

September 11th 2021

Gina Mauro

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Prognostic Risk Group, Receipt of Subsequent Therapies May Impact OS in mCRPC Receiving Lutetium 177

September 11th 2021

Kristi Rosa

Cancer and Leukemia Group B prognostic risk group and the receipt of subsequent FDA-approved life-prolonging therapies may impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.

Future of MPN Research, Treatment Revolves Around Addressing ‘A Main Problem’

September 11th 2021

Ryan McDonald

Although there are several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.

Nadofaragene Firadenovec Sustains Efficacy in Advanced NMIBC in Longer-Term Follow-Up

September 11th 2021

Brittany Lovely

Nadofaragene firadenovec, a novel intravesical gene therapy for patients with bacillus Calmette-Guérin unresponsive non–muscle invasive bladder cancer, demonstrated sustained durability according to findings from 2 cohorts of a phase 3 study.

Relugolix Induces Similar Rates of Castration Resistance–Free Survival Vs Leuprolide in Advanced Prostate Cancer

September 11th 2021

Jessica Hergert

Relugolix failed to significantly delay onset of castration resistance compared with standard of care leuprolide in men with advanced prostate cancer.

Durvalumab/Vicineum Combo Shows Early Safety, Activity in High-Grade NMIBC

September 11th 2021

Gina Mauro

The combination of durvalumab and Vicineum was found to be well tolerated and to elicit complete responses in patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer.

Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer

September 11th 2021

Kyle Doherty

Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.

Racial, Social Disparities Linked With T-Cell Lymphoma Outcomes

September 11th 2021

Conor Killmurray

Existing racial and socioeconomic disparities among patients with T-cell non-Hodgkin lymphoma continue to lead to obstacles with access for newly available treatment options.

Ruxolitinib Represents a Key Clinical Tool in Polycythemia Vera Paradigm

September 11th 2021

Sara Karlovitch

The JAK1/JAK2 inhibitor ruxolitinib has several clinical uses in the treatment of patients with polycythemia vera and plays an especially important role in adult patients who have had an inadequate response to hydroxyurea.

Sequential Crizotinib Followed by Alectinib Associated With Survival Benefit in ALK+ NSCLC

September 11th 2021

Jessica Hergert

Frontline sequential therapy with crizotinib followed by alectinib demonstrated survival benefits for patients with ALK-positive non–small cell lung cancer who develop resistance to, or become intolerant of crizotinib.

MRD-Based Consolidation Dara-KRd Elicits Rapid Responses in Newly Diagnosed Myeloma

September 11th 2021

Hayley Virgil

Minimal residual disease–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone was found to induce quick responses and unprecedented rates of MRD negativity in patients with newly diagnosed multiple myeloma.

TAR-200/Cetrelimab Under Investigation in Muscle-Invasive Bladder Cancer

September 11th 2021

Jason Harris

TAR-200 plus cetrelimab may offer a superior treatment option for patients with muscle-invasive bladder cancer, and to answer this questions, investigators have initiated the randomized, phase 3 SunRISe-2 trial.

Nivolumab Plus Ipilimumab Response Signals Change for Cytoreductive Nephrectomy in Advanced RCC

September 11th 2021

Jackie Collins

Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben Mesa, MD

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

See All News